The amino-acid stress sensing eIF2α kinase GCN2 is a survival biomarker for malignant mesothelioma
Gold, L.T., Bray, S.E., Kernohan, N.M. et al.
BJC Rep 1, 4 (2022). https://doi.org/10.1038/s44276-023-00004-y
BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification.
Barnett SE, Kenyani J, Tripari M, Butt Z, Grosman R, Querques F, Shaw L, Silva LC, Goate Z, Marciniak SJ, Rassl DM, Jackson R, Lian LY, Szlosarek PW, Sacco JJ, Coulson JM.
Mol Cancer Res. 2023 Jan 20:MCR-22-0635. doi: 10.1158/1541-7786.MCR-22-0635. Epub ahead of print. PMID: 36669126.
The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation.
Barnett, S.E.; Herrmann, A.; Shaw, L.; Gash, E.N.; Poptani, H.; Sacco, J.J.; Coulson, J.M.
Cancers 2022, 14, 5836. https://doi.org/ 10.3390/cancers14235836.
Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application.
Majumder P, Singh A, Wang Z, Dutta K, Pahwa R, Liang C, Andrews C, Patel NL, Shi J, de Val N, Walsh STR, Jeon AB, Karim B, Hoang CD, Schneider JP.
Nat Nanotechnol. 2021 Nov;16(11):1251-1259. doi: 10.1038/s41565-021-00961-w. Epub 2021 Sep 23. PMID: 34556833; PMCID: PMC8595541.
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, Borg E, Falzon M, Shah K, Kumar N, Janes SM.
J Biol Chem. 2021 Nov;297(5):101223. doi: 10.1016/j.jbc.2021.101223. Epub 2021 Sep 29. PMID: 34597666; PMCID: PMC8545693.
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis.
Singh A, Pruett N, Pahwa R, Mahajan AP, Schrump DS, Hoang CD.
Mol Ther Nucleic Acids. 2021 Apr 3;24:669-681. doi: 10.1016/j.omtn.2021.04.001. PMID: 33996251; PMCID: PMC8093312.
Integrated genomics point to immune vulnerabilities in pleural mesothelioma.
Nastase A, Mandal A, Lu SK, Anbunathan H, Morris-Rosendahl D, Zhang YZ, Sun XM, Gennatas S, Rintoul RC, Edwards M, Bowman A, Chernova T, Benepal T, Lim E, Taylor AN, Nicholson AG, Popat S, Willis AE, MacFarlane M, Lathrop M, Bowcock AM, Moffatt MF, Cookson WOCM.
Sci Rep. 2021 Sep 27;11(1):19138. doi: 10.1038/s41598-021-98414-w. PMID: 34580349; PMCID: PMC8476593.
Biological basis for novel mesothelioma therapies.
Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ.
Br J Cancer. 2021 Oct;125(8):1039-1055. doi: 10.1038/s41416-021-01462-2. Epub 2021 Jul 5. PMID: 34226685; PMCID: PMC8505556.
Use of preclinical models for malignant pleural mesothelioma.
Shamseddin M, Obacz J, Garnett MJ, Rintoul RC, Francies HE, Marciniak SJ.
Thorax. 2021 Nov;76(11):1154-1162. doi: 10.1136/thoraxjnl-2020-216602. Epub 2021 Mar 10. PMID: 33692175; PMCID: PMC8526879.
Normal mesothelial cell lines newly derived from human pleural biopsy explants.
Pruett N, Singh A, Shankar A, Schrump DS, Hoang CD
Am J Physiol Lung Cell Mol Physiol. 2020 Oct 1;319(4):L652-L660. doi: 10.1152/ajplung.00141.2020. Epub 2020 Jul 29. PMID: 32726133; PMCID: PMC764289
Exploring High Aspect Ratio Gold Nanotubes as Cytosolic Agents: Structural Engineering and Uptake into Mesothelioma Cells.
Ye S, Azad AA, Chambers JE, Beckett AJ, Roach L, Moorcroft SCT, Aslam Z, Prior IA, Markham AF, Coletta PL, Marciniak SJ, Evans SD.
Small. 2020 Nov;16(46):e2003793. doi: 10.1002/smll.202003793. Epub 2020 Oct 25. PMID: 33103323.
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.
Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.
Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.
MesobanK UK: an international mesothelioma bioresource.
Rintoul RC, Rassl DM, Gittins J, Marciniak SJ; MesobanK collaborators.
Thorax. 2016 Apr;71(4):380-2. doi: 10.1136/thoraxjnl-2015-207496.
